Vincent H Ha1, Margaret Ngo2, Michael P Chu3, Sunita Ghosh4, Michael B Sawyer5, Carole R Chambers6. 1. Pharmacy Department, Cross Cancer Institute, Canada Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada. 2. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada Pharmacy Department, Tom Baker Cancer Centre, Canada. 3. Department of Medical Oncology, Cross Cancer Institute, Canada. 4. Experimental Oncology Department, Cross Cancer Institute, Canada. 5. Department of Medical Oncology, Cross Cancer Institute, Canada Michael.Sawyer@albertahealthservices.ca. 6. Pharmacy Department, Cross Cancer Institute, Canada.
Abstract
INTRODUCTION: Renal cell cancer is a chemotherapy-insensitive cancer treated by vascular endothelial growth factor receptor antagonists. Recently, a question has arisen on whether there is an interaction between tyrosine kinase inhibitors, such as sunitinib, and acid suppressing agents. METHODS: A retrospective chart review was conducted for patients at two tertiary care centers who received sunitinib between 1 January 2006 and 31 March 2013. Using electronic systems and a province-wide electronic health records database, medication dispensing records were obtained. A univariate Cox's proportional hazard model determined if acid suppression had effects on progression-free survival and overall survival. RESULTS: Of 383 patient charts reviewed, 231 were included in the study. Patients on intermittent acid suppression, lost to follow-up or received sunitinib for less than one week were excluded from the study. The median age of the study population was 65. Patients who received no acid suppression (n = 186) had a median progression-free survival of 23.6 weeks (95% CI, 19.0-31.9 weeks) and patients who received continuous acid suppression (n = 45) had a median progression-free survival of 18.9 weeks (95% CI, 11.0-23.7 p = 0.04). A median overall survival of 62.4 weeks (95% CI, 42.0-82.7 weeks) was observed in the group with no acid suppression, while a median overall survival of 40.9 weeks (95% CI, 26.1-74.4 weeks) was observed in the continuous acid suppression group (p = 0.02). CONCLUSION: There was a significant difference in progression-free survival and overall survival between the acid suppressed and no acid suppression groups. Further research is required to confirm this potential interaction.
INTRODUCTION:Renal cell cancer is a chemotherapy-insensitive cancer treated by vascular endothelial growth factor receptor antagonists. Recently, a question has arisen on whether there is an interaction between tyrosine kinase inhibitors, such as sunitinib, and acid suppressing agents. METHODS: A retrospective chart review was conducted for patients at two tertiary care centers who received sunitinib between 1 January 2006 and 31 March 2013. Using electronic systems and a province-wide electronic health records database, medication dispensing records were obtained. A univariate Cox's proportional hazard model determined if acid suppression had effects on progression-free survival and overall survival. RESULTS: Of 383 patient charts reviewed, 231 were included in the study. Patients on intermittent acid suppression, lost to follow-up or received sunitinib for less than one week were excluded from the study. The median age of the study population was 65. Patients who received no acid suppression (n = 186) had a median progression-free survival of 23.6 weeks (95% CI, 19.0-31.9 weeks) and patients who received continuous acid suppression (n = 45) had a median progression-free survival of 18.9 weeks (95% CI, 11.0-23.7 p = 0.04). A median overall survival of 62.4 weeks (95% CI, 42.0-82.7 weeks) was observed in the group with no acid suppression, while a median overall survival of 40.9 weeks (95% CI, 26.1-74.4 weeks) was observed in the continuous acid suppression group (p = 0.02). CONCLUSION: There was a significant difference in progression-free survival and overall survival between the acid suppressed and no acid suppression groups. Further research is required to confirm this potential interaction.
Authors: Manvi Sharma; Holly M Holmes; Hemalkumar B Mehta; Hua Chen; Rajender R Aparasu; Ya-Chen T Shih; Sharon H Giordano; Michael L Johnson Journal: Cancer Date: 2019-01-03 Impact factor: 6.860
Authors: Michael P Chu; J Randolph Hecht; Dennis Slamon; Zev A Wainberg; Yung-Jue Bang; Paulo M Hoff; Alberto Sobrero; Shukui Qin; Karen Afenjar; Vincent Houe; Karen King; Sheryl Koski; Karen Mulder; Julie Price Hiller; Andrew Scarfe; Jennifer Spratlin; Yingjie J Huang; Saba Khan-Wasti; Neil Chua; Michael B Sawyer Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Roelof W F van Leeuwen; Frank G A Jansman; Nicole G Hunfeld; Robert Peric; Anna K L Reyners; Alex L T Imholz; Jacobus R B J Brouwers; Joachim G Aerts; Teun van Gelder; Ron H J Mathijssen Journal: Clin Pharmacokinet Date: 2017-07 Impact factor: 6.447